Literature DB >> 20369222

In vitro phage display in a rat beta cell line: a simple approach for the generation of a single-chain antibody targeting a novel beta cell-specific epitope.

S Ueberberg1, D Ziegler, W Schechinger, J W Dietrich, S Akinturk, H H Klein, S Schneider.   

Abstract

AIMS/HYPOTHESIS: The aim of the present study was to evaluate in vitro phage display in a beta cell line as a novel strategy for the isolation of beta cell-specific agents/biomarkers.
METHODS: A single-chain antibody (SCA) library was pre-incubated with AR42J cells in order to eliminate SCAs with exocrine binding properties. It was then panned against INS-1 cells to select beta cell-targeted antibodies.
RESULTS: By these means, we isolated a novel antibody, SCA B5, that binds rapidly (6.0 min) and with a 450-fold higher specificity to beta cells relative to exocrine cells. We estimated for SCA B5 a binding affinity in the low micromol/l range and 858 binding sites per beta cell. Confocal microscopy showed binding to the beta cell surface and confirmed subsequent internalisation. Moreover, staining of rat and human pancreatic tissue sections with SCA B5 suggests that the target epitope is presented in pancreatic beta cells of different origins. Infrared imaging revealed that labelling of beta cells with tracer SCA B5 is strictly dependent on beta cell mass. With competition assays we excluded insulin, glutamate decarboxylase, C-peptide and islet amyloid polypeptide as SCA B5 targets. In accordance with these predictions, SCA B5 homed in vivo highly selectively to normal beta cells and dysfunctional beta cells of diabetic rats. Moreover, accumulation of radioactively labelled SCA B5 in the pancreas was reduced by 80% after pre-injection with unlabelled SCA B5, thereby confirming the specific uptake in the pancreas. CONCLUSIONS/
INTERPRETATION: We report a simple strategy for the generation of an SCA targeting a novel beta cell-specific epitope.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20369222     DOI: 10.1007/s00125-010-1725-9

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  22 in total

1.  Quantitative evaluation of a monoclonal antibody and its fragment as potential markers for pancreatic beta cell mass.

Authors:  C S Hampe; A R Wallen; M Schlosser; M Ziegler; I R Sweet
Journal:  Exp Clin Endocrinol Diabetes       Date:  2005-07       Impact factor: 2.949

2.  A new technique for in vivo imaging of specific GLP-1 binding sites: first results in small rodents.

Authors:  Martin Gotthardt; Georg Lalyko; Julliëtte van Eerd-Vismale; Boris Keil; Tino Schurrat; Michael Hower; Peter Laverman; Thomas M Behr; Otto C Boerman; Burkhard Göke; Martin Béhé
Journal:  Regul Pept       Date:  2006-08-22

Review 3.  Current progress in non-invasive imaging of beta cell mass of the endocrine pancreas.

Authors:  Fabiola Souza; Matthew Freeby; Kristi Hultman; Norman Simpson; Alan Herron; Piotr Witkowsky; Eric Liu; Antonella Maffei; Paul E Harris
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

Review 4.  Islet mass and function in diabetes and transplantation.

Authors:  G C Weir; S Bonner-Weir; J L Leahy
Journal:  Diabetes       Date:  1990-04       Impact factor: 9.461

5.  Biopanning and rapid analysis of selective interactive ligands.

Authors:  R J Giordano; M Cardó-Vila; J Lahdenranta; R Pasqualini; W Arap
Journal:  Nat Med       Date:  2001-11       Impact factor: 53.440

6.  Peptide-mediated targeting of the islets of Langerhans.

Authors:  Kausar N Samli; Michael J McGuire; Christopher B Newgard; Stephen Albert Johnston; Kathlynn C Brown
Journal:  Diabetes       Date:  2005-07       Impact factor: 9.461

Review 7.  Phage library-screening: a powerful approach for generation of targeting-agents specific for normal pancreatic islet-cells and islet-cell carcinoma in vivo.

Authors:  S Ueberberg; S Schneider
Journal:  Regul Pept       Date:  2009-12-01

8.  Systematic screening of potential beta-cell imaging agents.

Authors:  Ian R Sweet; Daniel L Cook; Ake Lernmark; Carla J Greenbaum; Angela R Wallen; Erin S Marcum; Svetlana A Stekhova; Kenneth A Krohn
Journal:  Biochem Biophys Res Commun       Date:  2004-02-20       Impact factor: 3.575

9.  Efforts to develop methods for in vivo evaluation of the native beta-cell mass.

Authors:  S Schneider
Journal:  Diabetes Obes Metab       Date:  2008-11       Impact factor: 6.577

10.  Synthesis and evaluation of (S)-2-(2-[18F]fluoroethoxy)-4-([3-methyl-1-(2-piperidin-1-yl-phenyl)-butyl-carbamoyl]-methyl)-benzoic acid ([18F]repaglinide): a promising radioligand for quantification of pancreatic beta-cell mass with positron emission tomography (PET).

Authors:  B Wängler; S Schneider; O Thews; E Schirrmacher; S Comagic; P Feilen; C Schwanstecher; M Schwanstecher; C-Y Shiue; A Alavi; S Höhnemann; M Piel; F Rösch; R Schirrmacher
Journal:  Nucl Med Biol       Date:  2004-07       Impact factor: 2.408

View more
  6 in total

1.  Unique sphingomyelin patches are targets of a beta-cell-specific antibody.

Authors:  Amol Kavishwar; Zdravka Medarova; Anna Moore
Journal:  J Lipid Res       Date:  2011-07-11       Impact factor: 5.922

2.  Pancreatic islet and progenitor cell surface markers with cell sorting potential.

Authors:  J Hald; T Galbo; C Rescan; L Radzikowski; A E Sprinkel; H Heimberg; J Ahnfelt-Rønne; J Jensen; R Scharfmann; G Gradwohl; K H Kaestner; C Stoeckert; J N Jensen; O D Madsen
Journal:  Diabetologia       Date:  2011-09-23       Impact factor: 10.122

Review 3.  Targeting Type 1 Diabetes: Selective Approaches for New Therapies.

Authors:  Daniel F Sheehy; Sean P Quinnell; Arturo J Vegas
Journal:  Biochemistry       Date:  2019-01-17       Impact factor: 3.162

Review 4.  Imaging metabolic syndrome.

Authors:  Weiping Han; Kai-Hsiang Chuang; Young-Tae Chang; Malini Olivo; S Sendhil Velan; Kishore Bhakoo; David Townsend; George K Radda
Journal:  EMBO Mol Med       Date:  2010-06       Impact factor: 12.137

5.  Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization.

Authors:  Paul A Allegretti; Timothy M Horton; Yassan Abdolazimi; Hannah P Moeller; Benjamin Yeh; Matthew Caffet; Guillermina Michel; Mark Smith; Justin P Annes
Journal:  Bioorg Med Chem       Date:  2019-11-11       Impact factor: 3.641

Review 6.  Peptide YY: more than just an appetite regulator.

Authors:  Shanta J Persaud; Gavin A Bewick
Journal:  Diabetologia       Date:  2014-06-11       Impact factor: 10.122

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.